1. Home
  2. TRAK vs IKT Comparison

TRAK vs IKT Comparison

Compare TRAK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$8.72

Market Cap

212.5M

Sector

Technology

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
IKT
Founded
1990
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.5M
201.3M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
TRAK
IKT
Price
$8.72
$1.95
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.00
AVG Volume (30 Days)
115.5K
2.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.94%
N/A
EPS Growth
20.69
67.51
EPS
0.18
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
N/A
Revenue Next Year
$10.04
N/A
P/E Ratio
$47.17
N/A
Revenue Growth
4.84
N/A
52 Week Low
$8.11
$1.33
52 Week High
$23.72
$2.58

Technical Indicators

Market Signals
Indicator
TRAK
IKT
Relative Strength Index (RSI) 31.90 57.80
Support Level $8.11 $1.45
Resistance Level $10.75 $2.14
Average True Range (ATR) 0.42 0.14
MACD 0.01 0.02
Stochastic Oscillator 24.43 52.31

Price Performance

Historical Comparison
TRAK
IKT

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: